Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.
Novavax, Inc. (NASDAQ: NVAX) is a biotechnology company focused on vaccines, using a platform that combines protein-based nanoparticles with its proprietary Matrix-M® adjuvant. News about Novavax often centers on its COVID-19 vaccine Nuvaxovid™/Nuvaxovid®, its broader infectious disease pipeline, and the progress of key partnerships and collaborations.
Recent announcements highlight Novavax’s collaboration and license agreement with Sanofi, under which Sanofi has taken on lead commercial and regulatory responsibilities for Nuvaxovid in selected markets. News items cover marketing authorization transfers in the European Union and United States, milestone payments to Novavax, and Sanofi’s clinical data on combination vaccine candidates that incorporate Nuvaxovid and Matrix-M. Updates also describe regulatory approvals in markets such as Japan through partner Takeda, triggering additional milestone payments and royalty opportunities.
Investors following NVAX news will see regular coverage of quarterly financial results, revenue composition from product sales, supply sales and licensing and royalty streams, as well as information on Novavax’s site consolidation and cost footprint in Maryland. The company’s communications also describe early-stage research on vaccine candidates for shingles, Clostridioides difficile colitis and respiratory syncytial virus combinations, and the use of Matrix-M in the R21/Matrix-M malaria vaccine developed with Serum Institute of India and Oxford University.
This page aggregates press releases, conference participation announcements, regulatory updates and other material events related to Novavax. Readers can use it to monitor developments in the company’s vaccine programs, partnership milestones, capital structure transactions and strategic transformation as disclosed in public statements.
Novavax, Inc. (Nasdaq: NVAX) will report its fourth quarter and full year 2021 financial results on February 28, 2022, after U.S. markets close. The conference call is scheduled for 4:30 p.m. EST, with a replay available from 7:30 p.m. EST until March 7, 2022. Novavax is focused on next-generation vaccines, including its COVID-19 vaccine, which has received conditional authorization globally. The company is also developing a COVID-seasonal influenza combination vaccine, currently in a Phase 1/2 clinical trial.
Novavax, Inc. announced that Health Canada has authorized the use of its COVID-19 vaccine, Nuvaxovid™, for individuals aged 18 and older. This protein-based vaccine is the first of its kind approved in Canada. The authorization follows extensive preclinical and clinical trial data, including two pivotal Phase 3 trials demonstrating efficacy and a favorable safety profile. Novavax also has a supply agreement for 52 million doses with the Canadian government. The company plans to start manufacturing the vaccine at the National Research Council's facility in Montreal later this year.
Novavax, Inc. (Nasdaq: NVAX) announced on February 14, 2022, that the Singapore Health Sciences Authority (HSA) granted interim authorization for its Nuvaxovid™ COVID-19 vaccine. This vaccine is the first protein-based option authorized in Singapore for individuals 18 and older. The authorization follows the submission of data from pivotal Phase 3 trials, demonstrating efficacy and a favorable safety profile. Initial doses are projected to arrive in Singapore by the end of March. While Nuvaxovid is authorized in Singapore, it has yet to receive FDA approval for use in the U.S.
Novavax, Inc. (Nasdaq: NVAX) announced the submission for conditional marketing authorization (CMA) of its COVID-19 vaccine candidate NVX-CoV2373 to Swissmedic on February 14, 2022. The vaccine, utilizing a recombinant nanoparticle protein-based approach with Matrix-M™ adjuvant, has demonstrated efficacy in pivotal Phase 3 trials comprising approximately 45,000 participants in the U.S., Mexico, and U.K. Novavax aims to address vaccination gaps in Switzerland. The vaccine has already received conditional authorizations from multiple global regulatory agencies, including the European Commission and WHO.
Novavax, a biotechnology company, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022. The discussion will focus on NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine candidate. The chat is scheduled from 11:20 to 11:50 a.m. EST, moderated by David Risinger, featuring executives Filip Dubovsky and John J. Trizzino. A recorded replay will be available on the company’s website for 90 days.
Novavax (NVAX) announced that its COVID-19 vaccine, NVX-CoV2373, met primary effectiveness endpoints in the PREVENT-19 trial's pediatric expansion for adolescents aged 12-17. The trial, involving 2,247 participants, demonstrated 82% clinical efficacy against the Delta variant and showed robust immune responses, significantly higher than those in adults. The vaccine displayed a reassuring safety profile with no safety signals identified. Novavax plans to submit pediatric data for regulatory filings in Q1 2022, aiming for broader vaccine access in over 170 countries.
Novavax, Inc. (Nasdaq: NVAX) has received provisional approval from New Zealand's Medsafe for its COVID-19 vaccine, NVX-CoV2373, branded as Nuvaxovid. This approval allows the vaccine to be used for individuals aged 18 and older. The decision follows extensive evaluations from two pivotal Phase 3 trials, showing efficacy rates of 90.4% and 89.7% in the U.S. and U.K. respectively. The vaccine, supplied through a partnership with Serum Institute of India, is part of an advance purchase agreement for 10.7 million doses. Novavax remains committed to monitoring the vaccine's safety and effectiveness.
Novavax has received conditional marketing authorization from the MHRA for its Nuvaxovid™ COVID-19 vaccine in Great Britain, marking it as the first protein-based vaccine authorized there. This decision is based on data from significant clinical trials, including a Phase 3 trial in the U.K. with nearly 15,000 participants and another in the U.S. and Mexico with approximately 30,000 participants, showcasing efficacy rates of 89.7% and 90.4%, respectively. An agreement for 60 million doses was also previously established with the U.K. Vaccines Taskforce.
Novavax, Inc. has submitted a request for Emergency Use Authorization (EUA) to the FDA for its COVID-19 vaccine candidate, NVX-CoV2373. This request is supported by pivotal clinical trial data demonstrating an overall efficacy of approximately 90% in the PREVENT-19 trial involving 30,000 participants. The vaccine has a favorable safety profile and has received conditional authorization from multiple global regulatory agencies, including the EU and WHO. Novavax aims to provide an alternative vaccine option, leveraging its proprietary protein-based technology and global partnerships.
Novavax, Inc. (Nasdaq: NVAX) announces an advance purchase agreement with Israel's Ministry of Health for its COVID-19 vaccine, NVX-CoV2373. This agreement includes an initial 5 million doses with an option for an additional 5 million. The vaccine, which has shown high efficacy in ongoing Phase 3 trials, is awaiting regulatory approvals for distribution in Israel. The company has received conditional marketing authorization from the European Union and emergency use listing from the WHO. Novavax continues to monitor safety and efficacy while expanding its manufacturing capabilities worldwide.